AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CSL LIMITED

175.160

+1.1700.67%

Volume:859.42K

Turnover:170.99M

Market Cap:84.98B

PE:18.77

High:176.320

Open:175.000

Low:174.720

Close:173.990

52wk High:284.738

52wk Low:168.000

Shares:485.15M

Float Shares:483.95M

Volume Ratio:1.11

T/O Rate:0.18%

Dividend:4.42

Dividend Rate:2.52%

EPS(TTM):9.333

EPS(LYR):9.382

ROE:15.37%

ROA:6.63%

PB:2.91

PE(LYR):18.67

Loading ...

Overview Company News Filings

BUZZ-Macquarie cuts PT, downgrades rating for Australia's CSL on weaker outlook

CSL (ASX:CSL) Valuation Check After Robust Five-Year HEMGENIX Gene Therapy Results

Simply Wall St.

Did Five-Year HEMGENIX Data Just Shift CSL's (ASX:CSL) Gene Therapy Investment Narrative?

Simply Wall St.

Is CSL Stock a Rare Bargain at $180?

CSL Finance Appoints Chief Business Officer; Shares Up 3%

MT Newswires Live

Shares of CSL Fall After Audit Office Statement on Unit's Vaccine Deal

MT Newswires Live

BUZZ-Jefferies sees CSL's China albumin hit as short-term; keeps PT unchanged

CSL Reports Five-Year Data Confirming Long-Term Safety and Efficacy of HEMGENIX for Hemophilia B

The 2025 AGM Season Shows Shareholder Scrutiny, Focus on Board Accountability, Says Jarden

MT Newswires Live

BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound

Australian shares end lower as banks slip on rate worries

14 ASX stock ideas ahead of the next RBA hike (and the ones most at risk)

Australian shares close marginally higher; tech shines, commodity stocks dip

Alan Kohler: The grass is always greener on the other side

We’re not in Kansas anymore

Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A

CSL (ASX:CSL) Valuation in Focus After $1.5 Billion US Expansion Plan Announced

Simply Wall St.

CSL Ltd-Update - Notification of Buy-Back - CSL

THOMSON REUTERS

When markets get tricky, you need horsepower. VanEck's ALFA has it

Top stocks: Morgans' Raymond Chan shares his tips for the dip

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSL.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","market":"AU","secType":"STK","nameCN":"CSL LIMITED","latestPrice":175.16,"timestamp":1766112842412,"preClose":173.99,"halted":0,"volume":859415,"delay":0,"nameEN":"CSL LIMITED","floatShares":483950454,"shares":485151394,"eps":9.333493177623817,"marketStatus":"Trading","change":1.17,"latestTime":"12-19 13:54:02 AEDT","open":175,"high":176.32,"low":174.72,"amount":170989805,"amplitude":0.009196,"askPrice":175.2,"askSize":44,"bidPrice":175.16,"bidSize":16,"shortable":3,"etf":0,"ttmEps":9.333493177623817,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766120400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":173.99,"dividendRate":0.025114,"openAndCloseTimeList":[[1766098800000,1766120400000]],"volumeRatio":1.105043,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CSL.AU\",,,,,undefined,":{"symbol":"CSL.AU","floatShares":483950454,"roa":"6.63%","roe":"15.37%","lyrEps":9.381831,"volumeRatio":1.105043,"shares":485151394,"dividePrice":4.417148,"high":176.32,"amplitude":0.009196,"preClose":173.99,"low":174.72,"week52Low":168,"pbRate":"2.91","psRate":"3.61","week52High":284.738,"institutionHeld":0,"latestPrice":175.16,"committee":-0.466667,"eps":9.333493177623817,"divideRate":0.025218,"volume":859415,"delay":0,"ttmEps":9.333493177623817,"open":175,"prevYearClose":276.117,"prevWeekClose":183.93,"prevMonthClose":186.3,"prevQuarterClose":198.2,"fiveDayClose":183.93,"twentyDayClose":178.85,"sixtyDayClose":194.23,"dividendPayoutRate":0.4488044711953849,"dividendGrowthYears":4,"dividendGrowthRate":0.11620984529927163,"fiveYearAvgDividendRate":0.013182154300910737},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSL.AU\",params:#limit:5,,,undefined,":[{"date":"2026-02-09","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1770591600000,"name":null,"time":"","dateTimestamp":1770555600000,"actualEps":null},{"date":"2025-09-09","symbol":"CSL.AU","amount":1.62,"announcedDate":"2025-08-19","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-10","defaultRemindTime":1757376000000,"name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-03","payableDate":"2025-09-10","currency":"USD","dateTimestamp":1757340000000,"payDate":"2025-10-03"},{"date":"2025-08-19","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755561600000,"name":null,"time":"","dateTimestamp":1755525600000,"actualEps":null},{"date":"2025-03-10","symbol":"CSL.AU","amount":1.3,"announcedDate":"2025-02-11","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-03-11","name":"CSL LIMITED","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-09","payableDate":"2025-03-11","currency":"USD","dateTimestamp":1741525200000,"payDate":"2025-04-09"},{"date":"2025-02-11","symbol":"CSL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739228400000,"name":null,"time":"","dateTimestamp":1739192400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-10","recordDate":"2020-09-11","paymentDate":"2020-10-09","value":1.469578,"currency":"AUD"},{"executeDate":"2021-03-04","recordDate":"2021-03-05","paymentDate":"2021-04-01","value":1.04,"currency":"USD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-30","value":1.062,"currency":"USD"},{"executeDate":"2022-03-07","recordDate":"2022-03-08","paymentDate":"2022-04-06","value":1.04,"currency":"USD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-10-05","value":1.062,"currency":"USD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSL.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591679076","title":"BUZZ-Macquarie cuts PT, downgrades rating for Australia's CSL on weaker outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2591679076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591679076?lang=en_us&edition=fundamental","pubTime":"2025-12-15 06:50","pubTimestamp":1765752612,"startTime":"0","endTime":"0","summary":"BUZZ-Macquarie cuts PT, downgrades rating for Australia's CSL on weaker outlook** Macquarie cuts PT for Australia's CSL CSL.AX to A$188 from A$275 and downgrades stock to \"neutral\" from \"outperform\" ** Trims EPS estimates for biotech firm by 4%, 5% and 5% for FY26, FY27 and FY28 respectively, reflecting downgraded guidance due to softer performance at Seqirus, among others**  Sees risk to co's FY26 guidance with 2H reliant on containing China's albumin impacts** Estimates 25% of CSL Behring's immunoglobulin share in Chronic Inflammatory Demyelinating Polyneuropathy is at risk, which could result in a 4% EPS impact by FY33. ** Average rating of 16 analysts is \"buy\"; their median PT is A$237 – according to data compiled by LSEG ** Stock down 34.7% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251214:nL1N3XK078:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CSL.AU","BK7501","BK7511","BK7508"],"gpt_icon":0},{"id":"2590344577","title":"CSL (ASX:CSL) Valuation Check After Robust Five-Year HEMGENIX Gene Therapy Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344577","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590344577?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:41","pubTimestamp":1765514463,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has sparked fresh interest after unveiling five year HOPE B trial results for its gene therapy HEMGENIX, showing sustained efficacy and safety that could reshape reimbursement debates, especially in Australia.\nSee our latest analysis for CSL.\nYet despite a string of positives, from the new Melbourne vaccine facility to the ongoing buy-back and now the standout HEMGENIX data, CSL’s 1 year total shareholder return of around minus 34 percent and steep year to date share price...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-check-after-robust-five-year-hemgenix-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-check-after-robust-five-year-hemgenix-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","SG9999004303.SGD","BK7508","LU0728928796.USD","BK7511","CSL","LU1169589451.USD","LU1169590202.USD","BK7501","BK4086","CSL.AU","SGXZ23171101.USD"],"gpt_icon":0},{"id":"2590569274","title":"Did Five-Year HEMGENIX Data Just Shift CSL's (ASX:CSL) Gene Therapy Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590569274","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590569274?lang=en_us&edition=fundamental","pubTime":"2025-12-11 08:41","pubTimestamp":1765413678,"startTime":"0","endTime":"0","summary":"CSL recently reported five-year Phase 3 HOPE-B data in NEJM and at the ASH meeting, showing HEMGENIX’s durable factor IX activity, sustained bleed reduction, and continued freedom from routine prophylaxis in adults with hemophilia B.\nThe results reinforce HEMGENIX’s position as the only commercially available gene therapy for adult hemophilia B, with long-term safety and efficacy data that may shape how patients and clinicians view one-time gene therapy versus ongoing prophylaxis.\nWe’ll now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/did-five-year-hemgenix-data-just-shift-csls-asxcsl-gene-ther","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/did-five-year-hemgenix-data-just-shift-csls-asxcsl-gene-ther","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4086","LU1169590202.USD","SG9999004303.SGD","BK7067","CSL","LU1169589451.USD","BK7501","BK7508","BK7511","LU0728928796.USD","SGXZ23171101.USD","CSL.AU"],"gpt_icon":0},{"id":"1137833880","title":"Is CSL Stock a Rare Bargain at $180?","url":"https://stock-news.laohu8.com/highlight/detail?id=1137833880","media":"Trading Random","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137833880?lang=en_us&edition=fundamental","pubTime":"2025-12-10 13:16","pubTimestamp":1765343768,"startTime":"0","endTime":"0","summary":"The CSL Ltd (ASX: CSL) stock has faced consistent pressure over the past couple of years, sparking investor speculation: Is this one of those rare opportunities to buy a top-tier blue-chip at a...","market":null,"thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Is CSL Stock a Rare Bargain at $180?","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSL.AU"],"gpt_icon":0},{"id":"2590315759","title":"CSL Finance Appoints Chief Business Officer; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590315759","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590315759?lang=en_us&edition=fundamental","pubTime":"2025-12-09 16:14","pubTimestamp":1765268064,"startTime":"0","endTime":"0","summary":"CSL Finance (NSE:CSLFINANCE, BOM:530067) has appointed Prince Bhardwaj as the chief business officer with effect from Tuesday, according to a same-day disclosure to the Indian stock exchanges.The company's shares were up over 3% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","BK4086","LU1169590202.USD","BK7508","CSL","BK7501","CSL.AU","LU1169589451.USD","SG9999004303.SGD","LU0728928796.USD","BK7511","BK7067"],"gpt_icon":0},{"id":"2590939336","title":"Shares of CSL Fall After Audit Office Statement on Unit's Vaccine Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2590939336","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590939336?lang=en_us&edition=fundamental","pubTime":"2025-12-09 10:00","pubTimestamp":1765245608,"startTime":"0","endTime":"0","summary":"Shares of CSL  fell 1% in recent Tuesday trade after the Australian National Audit Office said in a Monday statement that the procurement of onshore manufacturing capability for antivenoms and vaccines by the company's unit Seqirus \"did not maximize value for money for the Australian taxpayer in the long term.\"The office said the procurements needed earlier planning and clearer value-for-money conclusions.CSL did not immediately respond to MT Newswires' email request for comment.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SGXZ23171101.USD","BK4086","LU1169590202.USD","BK7508","CSL","BK7501","CSL.AU","LU1169589451.USD","SG9999004303.SGD","LU0728928796.USD","BK7511","BK7067"],"gpt_icon":0},{"id":"2590684243","title":"BUZZ-Jefferies sees CSL's China albumin hit as short-term; keeps PT unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2590684243","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590684243?lang=en_us&edition=fundamental","pubTime":"2025-12-09 03:20","pubTimestamp":1765221652,"startTime":"0","endTime":"0","summary":"BUZZ-Jefferies sees CSL's China albumin hit as short-term; keeps PT unchanged** Jefferies in a note analysed the impact of China's measures on albumin on Australia's CSL Ltd CSL.AX** Albumin is used to replace lost fluids and restore blood volume in the human body** Brokerage keeps price target unchanged for the biotech major at A$237; maintains \"buy\" rating** Says cost containment in China weighing on albumin demand, mainly in H1 FY26, but sees rebound from H2 FY26** Cost containment measures affecting albumin demand include reimbursement limits, centralized procurement, and pricing caps; CSL to offset via differentiated pricing and retail push** Estimates albumin penetration in Chinese hospitals is only about 15%, meaning there's still significant room for growth over time** Jefferies believe majority of CSL operates in a rational, underpenetrated environment** 12 of 16 analysts rate the stock \"buy\" or higher, four \"hold\"; their median PT is A$237, according to data compiled by LSEG*","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nL4N3XE1LS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2589237808","title":"CSL Reports Five-Year Data Confirming Long-Term Safety and Efficacy of HEMGENIX for Hemophilia B","url":"https://stock-news.laohu8.com/highlight/detail?id=2589237808","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589237808?lang=en_us&edition=fundamental","pubTime":"2025-12-08 01:01","pubTimestamp":1765126897,"startTime":"0","endTime":"0","summary":"CSL Limited has announced the five-year results from the pivotal Phase 3 HOPE-B study of HEMGENIX , a gene therapy for adults with hemophilia B. The results, published in the New England Journal of Medicine and presented at the American Society of Hematology  Annual Meeting, confirm the long-term durability and safety of a single infusion of HEMGENIX. Data show that 94% of patients remained free from continuous prophylaxis treatment five years post-infusion, with mean factor IX activity levels at 36.1%. The therapy continues to demonstrate a favorable safety profile. HEMGENIX is currently the only commercially available gene therapy for adults with hemophilia B and has received approvals in multiple countries. Participants from the HOPE-B study may continue to be monitored in an extended follow-up study for up to 15 years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL13L64H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2589865176","title":"The 2025 AGM Season Shows Shareholder Scrutiny, Focus on Board Accountability, Says Jarden","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865176","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589865176?lang=en_us&edition=fundamental","pubTime":"2025-12-05 13:43","pubTimestamp":1764913425,"startTime":"0","endTime":"0","summary":"The 2025 annual general meeting season reflected elevated shareholder scrutiny, with investors remaining focused on board accountability, credible remuneration design, and governance track records, ac","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NWH.AU","BK7501","BK7124","IEL.AU","BK7135","BK7132","BK7055","BK7012","BK7031","BK4229","BK7508","WBC.AU","RWC.AU","REH.AU","JHX.AU","AGM","NAB.AU","ACL.AU","BK4195","BK7067","ANZ.AU","CSL.AU","BK7044","BK7511"],"gpt_icon":0},{"id":"2588183026","title":"BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound","url":"https://stock-news.laohu8.com/highlight/detail?id=2588183026","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588183026?lang=en_us&edition=fundamental","pubTime":"2025-12-04 03:06","pubTimestamp":1764788779,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar sees Australia's CSL as 'cheap', optimistic for margin rebound** Morningstar says while CSL CSL.AX shares have lost around 40% since acquiring iron deficiency and kidney disease business Vifor in August 2022, several other factors have also contributed to the stock's lacklustre performance** Adds while the Vifor acquisition has diluted return on invested capital , Morningstar expects the segment to turn around and sees group ROIC to improve to CSL's pre-acquisition levels** Morningstar flags CSL's current plasma product pipeline is slim, with no expectation of significant earnings contribution** Investment research firm keeps fair value estimate at A$295, says stock screens \"cheap\"** Morningstar sees CSL's margins to rebound from restructuring, new high-margin products and plasma efficiency initiatives that have yet to completely flow through** CSL down 35.3% so far this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nL6N3X91FF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CSL.AU","BK7511","BK7501"],"gpt_icon":0},{"id":"2588749408","title":"Australian shares end lower as banks slip on rate worries","url":"https://stock-news.laohu8.com/highlight/detail?id=2588749408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588749408?lang=en_us&edition=fundamental","pubTime":"2025-12-01 14:41","pubTimestamp":1764571268,"startTime":"0","endTime":"0","summary":"Australian shares end lower as banks slip on rate worriesUpdates to closeS&P/ASX 200 falls 0.6%Banks close at their lowest level since mid-MayASX's announcements platform suffers outageAustralia's Q3 GDP report due on WednesdayBy Keshav SinghChundawat. Australian shares fell on Monday as heavyweight financials dragged the market lower, with valuation and margin worries mounting after recent economic data fuelled expectations that the central bank may have reached the end of its easing cycle.The benchmark S&P/ASX 200 index .AXJO closed 0.6% lower at 8,565.20 points. It slid 3% in November, marking its steepest monthly decline in eight months.Hotter inflation and stronger jobs data last month sealed the case that the Reserve Bank of Australia's policy easing cycle may be over. Swaps currently imply a split chance of a rate hike by the end of next year. Traders are waiting for the quarterly gross domestic product report on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X708C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7135","BK7101","BK7501","BK7508","BK7511","CBA.AU","CSL.AU","BK7067","AUB.AU"],"gpt_icon":0},{"id":"2588956745","title":"14 ASX stock ideas ahead of the next RBA hike (and the ones most at risk)","url":"https://stock-news.laohu8.com/highlight/detail?id=2588956745","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588956745?lang=en_us&edition=fundamental","pubTime":"2025-12-01 14:06","pubTimestamp":1764569181,"startTime":"0","endTime":"0","summary":"Macquarie has taken a deep dive into the past five RBA tightening cycles to uncover which ASX sectors reliably outperform before a rate hike - and which ones tend to lag.“We are increasingly closer to the beginning of [RBA] rate hikes,” the firm warns.“Hikes are a headwind for stocks, as they impact valuations today and earnings tomorrow. However, Fed cuts are a notable offset, supporting ongoing AI capex and US consumer spending.”Looking back at every tightening cycle since the early 1990s, Macquarie finds that ASX stocks delivered a median total shareholder return of nearly 8% in the 12 months leading up to the first hike. Returns were positive in all five cases - a reflection of the same lift in growth and inflation that pushes the RBA to tighten also driving stronger earnings.The sectors that lead the pack - and the 14 stocks to play them. Transport stocks are another beneficiary, though more yield-sensitive infrastructure names can lag. Momentum in Aurizon  and Orica  reflects the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/14-asx-stock-ideas-ahead-of-the-next-rba-hike-and-the-ones-most-at-risk","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/14-asx-stock-ideas-ahead-of-the-next-rba-hike-and-the-ones-most-at-risk","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["US12M.BOND","BK7086","BK7041","US10Y.BOND","ORG.AU","BK7160","BK7112","PRU.AU","PLS.AU","SUL.AU","CGF.AU","BK7067","MQG.AU","US2Y.BOND","ANZ.AU","S32.AU","BK7501","SUN.AU","WES.AU","BAP.AU","AGM.AU","US30Y.BOND","US6M.BOND","AFG.AU","PMV.AU","GMG.AU","BK4229","AGM","BK7046","CSL.AU","US5Y.BOND","SCG.AU","TLTW","BK7097","BK7087","US3Y.BOND","ORI.AU","US7Y.BOND","NST.AU","NAB.AU","BK7140","AZJ.AU","ALD.AU","RIO.AU","GMD.AU","TMF","ZIP.AU","MGR.AU","TWE.AU"],"gpt_icon":1},{"id":"2586211063","title":"Australian shares close marginally higher; tech shines, commodity stocks dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2586211063","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586211063?lang=en_us&edition=fundamental","pubTime":"2025-11-27 14:37","pubTimestamp":1764225422,"startTime":"0","endTime":"0","summary":"Australian shares close marginally higher; tech shines, commodity stocks dipUpdates to closeAXJO rises for a fourth straight sessionTech gains 2%, the energy sub-index falls 1.3%NZ50 ends 1% lowerBy Keshav SinghChundawat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nL4N3X309K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","LU0345777659.USD","LU0345777147.USD","IE00BQJZX424.USD","RIO.UK","IE00BWDBJ516.SGD","BK7067","BK7511","LU0171293334.USD","SG9999001143.SGD","BK5111","LU0345781412.USD","BK7508","LU0266512473.USD","LU0630314457.HKD","IE0034235071.USD","LU0011963245.USD","CSL.AU","LU0788109121.HKD","LU1064927863.SGD","BK7016","LU0898667661.SGD","WTC.AU","BK7507","LU1078025761.USD","LU2463526074.USD","IE00B3M56506.USD","BK7095","LU0266512127.USD","LU0612318385.USD","LU1430597077.USD","WDS.AU","LU0654597011.USD","LU1023059493.AUD","LU0161305163.EUR","LU0505663152.USD","LU0612318971.USD","LU0075056555.USD","LU0456854461.SGD","QBE.AU","LU0345780950.USD","LU0955669360.SGD","BK7034","BK7503","LU0330918003.SGD","SG9999002521.SGD","LU1130305938.SGD","BK7142","BHP.AU","LU0831103253.SGD"],"gpt_icon":0},{"id":"2586299378","title":"Alan Kohler: The grass is always greener on the other side","url":"https://stock-news.laohu8.com/highlight/detail?id=2586299378","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586299378?lang=en_us&edition=fundamental","pubTime":"2025-11-27 08:30","pubTimestamp":1764203407,"startTime":"0","endTime":"0","summary":"Investors are hardwired to compare themselves with whatever is running hottest at the time. When US tech stocks roar, the temptation is to look at the ASX and wonder why we bother. Yet Alan Kohler, one of the most recognisable voices in Australian finance, is entirely at ease with the slower and steadier returns on home soil. And after decades watching market cycles come and go, he has a simple message for anyone feeling twitchy about missing out.“We probably shouldn’t get too greedy,” he says.The local market has delivered a modest gain this year, but once you factor in dividends, total returns are north of 7 percent with a month still to run.It feels unremarkable only when stacked against the US, where the S&P 500 has surged on the back of an AI-fuelled boom. But Kohler’s view is that the extra sizzle in the US comes with baggage that many investors tend to forget until it is too late.Nvidia continues to deliver big numbers, but the market is slowly realising that its customer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/alan-kohler-the-grass-is-always-greener-on-the-other-side","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/alan-kohler-the-grass-is-always-greener-on-the-other-side","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["NVD","XJO.AU","BK7508","LU1066051498.USD","BK4579","LU0345770308.USD","NVDS","RMD.AU","LU1267930730.SGD","ARU.AU","LU2108987350.USD","2NVD.UK","NVDY","LU2413666699.HKD","LU2244417387.USD","LU2125909247.SGD","NVDA","NVIW.SI","COH.AU","BK4567","IE00BDCRKT87.USD","NVDD","XKO.AU","NVDS.UK","CSL.AU","SRL.AU","SNVD.UK","LU1934455277.USD","LU0683600562.USD","LU2592432038.USD","NVDU","LU0689626769.HKD","LU0466842654.USD","LU1815333072.USD","LU1116320737.USD","BK4554","NVD2.UK","LU2750360641.GBP","LU1551013342.USD","3NVD.UK","LU2473716301.USD","LMG.AU","LU1935043023.USD","XAO.AU","NVD3.UK","LU1868836591.USD","LU0342679015.USD","LU0203202063.USD"],"gpt_icon":1},{"id":"2586262069","title":"We’re not in Kansas anymore","url":"https://stock-news.laohu8.com/highlight/detail?id=2586262069","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586262069?lang=en_us&edition=fundamental","pubTime":"2025-11-27 04:15","pubTimestamp":1764188107,"startTime":"0","endTime":"0","summary":"One only needs to glance at a map of the US equity market to determine ‘We’re not in Kansas anymore’. The era of network economics and ever greater financialisation has wrought massive change on equity markets and increasingly on the real economy.Ever-growing government deficits and strong ongoing growth in household borrowing are funding a relatively buoyant profit environment, albeit one that is distributed increasingly unevenly. Disequilibrium is becoming the norm and the economic forces which tended to work against this are proving ineffective. While the reasons for this ongoing disequilibrium are debatable, a few seem important.Keen to display the power of monetary intervention in ‘smoothing’ economic cycles and preventing any downturn, central bankers everywhere have ensured additional credit and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/we-re-not-in-kansas-anymore","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/we-re-not-in-kansas-anymore","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["BK7067","BK7089","MQG.AU","BK7135","RHC.AU","BK7511","XJO.AU","BK7124","HLS.AU","XAO.AU","BK7046","ACL.AU","MPL.AU","BK7509","CBA.AU","BK7113","XKO.AU","BK7508","CSL.AU","SHL.AU","BK7501"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU1116320901.HKD","LU1934455194.USD","LU1430594728.SGD","LU2089984988.USD","IE000M9KFDE8.USD","CELC","USAW.SI","LU1037948897.HKD","LU2023250504.SGD","SGXZ57979304.SGD","BK7067","SG9999014559.SGD","QLD","BK4532",".IXIC","LU0861579265.USD","LU1934455277.USD","PFE","IE00B19Z3B42.SGD","USJW.SI","LU0238689110.USD","IE00BN8TJ469.HKD","NVS","BK4505","LU2324357040.USD","LU0265550946.USD","TQQQ","QURE","SQQQ","LU1057294990.SGD","CSL.AU","MNQmain","VRNA","NQmain","MRK","VIGL","IE00BSNM7G36.USD","LU1929549753.HKD","LU0289739699.SGD","LU0985320562.USD","RNA","QID","TSYW.SI","LU0098860793.USD","NVIW.SI","LU0265550359.USD","PSQ","BK4559","REPL"],"gpt_icon":1},{"id":"2585193422","title":"CSL (ASX:CSL) Valuation in Focus After $1.5 Billion US Expansion Plan Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=2585193422","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585193422?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:37","pubTimestamp":1763681861,"startTime":"0","endTime":"0","summary":"CSL (ASX:CSL) has announced a $1.5 billion investment over the next five years to expand its United States operations. This move is intended to boost the clinical supply of immunoglobulin and reinforce its domestic manufacturing base.\nSee our latest analysis for CSL.\nDespite CSL’s continued push to expand its U.S. presence and deepen its manufacturing capabilities, the shares have endured a challenging run, with a 1-year total shareholder return of -33.6%. Recent news about the $1.5 billion...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-in-focus-after-15-billion-us-expansion","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/csl-asxcsl-valuation-in-focus-after-15-billion-us-expansion","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","CSL","LU1169590202.USD","SG9999004303.SGD","BK7067","LU1169589451.USD","BK7501","BK4086","BK7511","CSL.AU","SGXZ23171101.USD","LU0728928796.USD"],"gpt_icon":0},{"id":"2585150989","title":"CSL Ltd-Update - Notification of Buy-Back - CSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2585150989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585150989?lang=en_us&edition=fundamental","pubTime":"2025-11-21 05:20","pubTimestamp":1763673624,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nTUE3BHB62:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","BK7511","CSL.AU"],"gpt_icon":0},{"id":"2584977055","title":"When markets get tricky, you need horsepower. VanEck's ALFA has it","url":"https://stock-news.laohu8.com/highlight/detail?id=2584977055","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584977055?lang=en_us&edition=fundamental","pubTime":"2025-11-20 09:14","pubTimestamp":1763601249,"startTime":"0","endTime":"0","summary":"Please note, this interview was filmed Thursday, 6 November 2025. The recent bout of market volatility is precisely why I've always liked long/short strategies. Executed well, they allow you to participate in most of the upside when it occurs, whilst also protecting you from the worst of the downside when it inevitably arrives.So, in a market crowded with ETFs of every flavour, when VanEck launched its Australian Long/Short Complex ETF , it immediately landed on my radar.Part of the appeal is the simple fact that long/short strategies are not easy to implement. They require both conviction and discipline. But what really intrigued me, and what ultimately forms the backbone of ALFA, is the way VanEck have blended quantitative horsepower with a fundamental framework - both of which continuously evolve. This isn’t a “set and forget” rulebook. It’s a living, learning engine running thousands of signals, hunting for mispricing across every corner of the ASX.McCormack frames the backdrop: th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/when-markets-get-tricky-you-need-horsepower-vaneck-s-alfa-has-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/when-markets-get-tricky-you-need-horsepower-vaneck-s-alfa-has-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["MVW.AU","BK7016","TNE.AU","QUAL.AU","FDN","BK4588","XKO.AU","CSL.AU","BK7508","QUAL","XJO.AU","XAO.AU","APE.AU","BK7501","ALFA.AU","ALFA","BK7143","BK7067","BK7503","BK7511","BK4585","BK4550"],"gpt_icon":0},{"id":"2584764169","title":"Top stocks: Morgans' Raymond Chan shares his tips for the dip","url":"https://stock-news.laohu8.com/highlight/detail?id=2584764169","media":"Switzer","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584764169?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:07","pubTimestamp":1763586478,"startTime":"0","endTime":"0","summary":"Raymond Chan, head of research at Morgans, has given us his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, and the stocks that might need a little more patience.","market":"hk","thumbnail":"https://switzer.com.au/wp-content/uploads/Raymond_chan_switzer_daily.png","type":0,"news_type":0,"thumbnails":["https://switzer.com.au/wp-content/uploads/Raymond_chan_switzer_daily.png"],"rights":{"source":"switzer_stock","url":"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"switzer_stock","symbols":["XRO.AU","LU0124384867.USD","LU0053671581.USD","LU0823414478.USD","PME","SG9999004303.SGD","LU0823414551.USD","LU1169589451.USD","BK7511","CSL","GMG.AU","SGXZ23171101.USD","BK7016","BK7501","LU1978683503.SGD","CSL.AU","LU2506951792.HKD","LU0724618433.USD","BK7155","BK4096","LU2298322129.HKD","LU1983299162.USD","NXT","BK7508","BK7503","BK7067","BK7099","LU2249611893.SGD","LU0312595415.SGD","LU1169590202.USD","LU2275660780.HKD","LU2357125470.USD","LU0728928796.USD","BK7510","BK4212","360.AU","LU0302445910.USD","BK4588","BK4596","LU2294711713.HKD","BK7094","BK4585","PME.AU","BK7043","NXT.AU","BK4086"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":196,"code":"91000000","status":"200"}]}}